Abstract
In the international phase III HERO study, the once-daily oral GnRH receptor antagonist, relugolix, demonstrated superior continuous suppression of testosterone to castrate levels through week 48 compared to LEU, and a 54% lower risk of major adverse cardiovascular events relative to LEU (Shore N, 2020 NEJM 382;23). To further characterize the geographical impact on the efficacy and safety of relugolix vs LEU in APC, a subgroup analysis of HERO was undertaken.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
